- Several months ahead of schedule, Aerie Pharmaceuticals (NASDAQ:AERI) has completed the enrollment of 215 open-angle glaucoma/ocular hypertension patients in a Phase 2 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (branded as Rhopressa in the U.S.) in this population. Topline results should be available in Q4.
- If successful, Phase 3 studies will follow.